Upon completion of this activity, the participant should be able to:

• Provide a high-yield overview of reproductive health in LT recipients, including the natural history of post-transplant fertility and recommended changes in pharmacotherapy (i.e., contraception and immunosuppression) in pregnant or breastfeeding LT recipients.
• Provide an updated, evidence-based summary of graft, maternal and fetal outcomes in liver transplant recipients.
• Emphasize the importance of a collaborative clinical relationship between transplant hepatologists, transplant surgeons, obstetricians and maternal-fetal-medicine specialists.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the speaker shall disclose to the audience that the product is not labeled for the use under discussion or that the product is still investigational.

Carla Brady, MD, MHS, FAASLD
Nothing to Disclose

Tatyana Kushner, MD, MSCE
Scientific Consultant: Gilead, HDV, Eiger, AbbVie, GlaxoSmithKline
Research Grants: Gilead, Icahn School of Medicine

Monika Sarkar, MD, MAS
Research Grants: Gilead Sciences, Zydus Pharmaceuticals, GlaxoSmithKline

Lisa Coscia, BSN, RN
Research Grants: Veloxis Pharmaceuticals

Avesh Thuluvath, MD, MS
Nothing to Disclose

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: December 10, 2024                                                Expiration Date: December 10, 2025

COPYRIGHT: All faculty in this presentation have given their permission for publication ©2024 AASLD.

Privacy Policy: https://www.aasld.org/terms-use-and-privacy-policy